Lineage Cell rises as eye treatment succeeds in early stage trial

Lineage Cell Therapeutics

05/10/2023 14:01

** Shares of Lineage Cell Therapeutics  LCTX.A  rise ~6.7%
to $1.28 premarket
    ** Co says its drug showed rapid improvement in the outer
retinal structure of the eye for patients with geographic
atrophy (GA) in an early-stage trial
    ** GA is an age-related degeneration of the eye that can
lead to irreversible loss of vision 
    ** Up to last close, shares up 2.6% YTD

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))